Grifols: Bankinter upgrades share
(CercleFinance.com) - Bankinter has upgraded its rating on the Grifols share from "sell" to "neutral," citing an improvement in the Spanish blood plasma group's leverage.
The fact that Grifols has taken a 26.2% stake in Shangai Rass Blood Products through contributing assets shows that the company's debt management has become "more conservative," the broker says.
"Results continue to have limited visibility, but showed signs of improvement in the second half of 2018", Bankinter added.
Bankinter has set its target price for the share at 25.5 euros, representing upside potential of 7%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The fact that Grifols has taken a 26.2% stake in Shangai Rass Blood Products through contributing assets shows that the company's debt management has become "more conservative," the broker says.
"Results continue to have limited visibility, but showed signs of improvement in the second half of 2018", Bankinter added.
Bankinter has set its target price for the share at 25.5 euros, representing upside potential of 7%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.